These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 26807544)

  • 1. Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions.
    Drinkwater N; Vinh NB; Mistry SN; Bamert RS; Ruggeri C; Holleran JP; Loganathan S; Paiardini A; Charman SA; Powell AK; Avery VM; McGowan S; Scammells PJ
    Eur J Med Chem; 2016 Mar; 110():43-64. PubMed ID: 26807544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-pronged attack: dual inhibition of Plasmodium falciparum M1 and M17 metalloaminopeptidases by a novel series of hydroxamic acid-based inhibitors.
    Mistry SN; Drinkwater N; Ruggeri C; Sivaraman KK; Loganathan S; Fletcher S; Drag M; Paiardini A; Avery VM; Scammells PJ; McGowan S
    J Med Chem; 2014 Nov; 57(21):9168-83. PubMed ID: 25299353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening the Medicines for Malaria Venture "Malaria Box" against the Plasmodium falciparum aminopeptidases, M1, M17 and M18.
    Paiardini A; Bamert RS; Kannan-Sivaraman K; Drinkwater N; Mistry SN; Scammells PJ; McGowan S
    PLoS One; 2015; 10(2):e0115859. PubMed ID: 25700165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.
    Vinh NB; Drinkwater N; Malcolm TR; Kassiou M; Lucantoni L; Grin PM; Butler GS; Duffy S; Overall CM; Avery VM; Scammells PJ; McGowan S
    J Med Chem; 2019 Jan; 62(2):622-640. PubMed ID: 30537832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and Validation of a Potent Dual Inhibitor of the P. falciparum M1 and M17 Aminopeptidases Using Virtual Screening.
    Ruggeri C; Drinkwater N; Sivaraman KK; Bamert RS; McGowan S; Paiardini A
    PLoS One; 2015; 10(9):e0138957. PubMed ID: 26406322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure of the Plasmodium falciparum M17 aminopeptidase and significance for the design of drugs targeting the neutral exopeptidases.
    McGowan S; Oellig CA; Birru WA; Caradoc-Davies TT; Stack CM; Lowther J; Skinner-Adams T; Mucha A; Kafarski P; Grembecka J; Trenholme KR; Buckle AM; Gardiner DL; Dalton JP; Whisstock JC
    Proc Natl Acad Sci U S A; 2010 Feb; 107(6):2449-54. PubMed ID: 20133789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. X-ray crystal structures of an orally available aminopeptidase inhibitor, Tosedostat, bound to anti-malarial drug targets PfA-M1 and PfA-M17.
    Drinkwater N; Bamert RS; Sivaraman KK; Paiardini A; McGowan S
    Proteins; 2015 Apr; 83(4):789-95. PubMed ID: 25645579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of PfA-M1, over PfA-M17, by an amino-benzosuberone derivative blocks malaria parasites development in vitro and in vivo.
    Bounaadja L; Schmitt M; Albrecht S; Mouray E; Tarnus C; Florent I
    Malar J; 2017 Sep; 16(1):382. PubMed ID: 28934959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based development of potent Plasmodium falciparum M1 and M17 aminopeptidase selective and dual inhibitors via S1'-region optimisation.
    Calic PPS; Vinh NB; Webb CT; Malcolm TR; Ngo A; Lowes K; Drinkwater N; McGowan S; Scammells PJ
    Eur J Med Chem; 2023 Feb; 248():115051. PubMed ID: 36634455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening and In Vitro Evaluation of Potential Plasmodium falciparum Leucyl Aminopeptidase Inhibitors.
    Chaudhary M; Singh V; Anvikar AR; Sahi S
    Curr Comput Aided Drug Des; 2016; 12(4):282-293. PubMed ID: 27449897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents.
    Flipo M; Beghyn T; Leroux V; Florent I; Deprez BP; Deprez-Poulain RF
    J Med Chem; 2007 Mar; 50(6):1322-34. PubMed ID: 17326615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic and chemical validation of
    Edgar RCS; Siddiqui G; Hjerrild K; Malcolm TR; Vinh NB; Webb CT; Holmes C; MacRaild CA; Chernih HC; Suen WW; Counihan NA; Creek DJ; Scammells PJ; McGowan S; de Koning-Ward TF
    Elife; 2022 Sep; 11():. PubMed ID: 36097817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling of human leucyl aminopeptidases for in silico off target binding analysis of potential Plasmodium falciparum leucine aminopeptidase (PfA-M17) specific inhibitors.
    Sahi S; Raj U; Chaudhary M; Nain V
    Recent Pat Endocr Metab Immune Drug Discov; 2014; 8(3):191-201. PubMed ID: 25269653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KBE009: An antimalarial bestatin-like inhibitor of the Plasmodium falciparum M1 aminopeptidase discovered in an Ugi multicomponent reaction-derived peptidomimetic library.
    González-Bacerio J; Maluf SEC; Méndez Y; Pascual I; Florent I; Melo PMS; Budu A; Ferreira JC; Moreno E; Carmona AK; Rivera DG; Alonso Del Rivero M; Gazarini ML
    Bioorg Med Chem; 2017 Sep; 25(17):4628-4636. PubMed ID: 28728898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoproteomics validates selective targeting of
    Giannangelo C; Challis MP; Siddiqui G; Edgar R; Malcolm TR; Webb CT; Drinkwater N; Vinh N; Macraild C; Counihan N; Duffy S; Wittlin S; Devine SM; Avery VM; De Koning-Ward T; Scammells P; McGowan S; Creek DJ
    Elife; 2024 Jul; 13():. PubMed ID: 38976500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity.
    Edgar RCS; Malcolm TR; Siddiqui G; Giannangelo C; Counihan NA; Challis M; Duffy S; Chowdhury M; Marfurt J; Dans M; Wirjanata G; Noviyanti R; Daware K; Suraweera CD; Price RN; Wittlin S; Avery VM; Drinkwater N; Charman SA; Creek DJ; de Koning-Ward TF; Scammells PJ; McGowan S
    mBio; 2024 Jun; 15(6):e0096624. PubMed ID: 38717141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemical target validation studies of aminopeptidase in malaria parasites using alpha-aminoalkylphosphonate and phosphonopeptide inhibitors.
    Cunningham E; Drag M; Kafarski P; Bell A
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3221-8. PubMed ID: 18458130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping the Pathway and Dynamics of Bestatin Inhibition of the Plasmodium falciparum M1 Aminopeptidase PfA-M1.
    Yang W; Riley BT; Lei X; Porebski BT; Kass I; Buckle AM; McGowan S
    ChemMedChem; 2018 Dec; 13(23):2504-2513. PubMed ID: 30318749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasmodium falciparum neutral aminopeptidases: new targets for anti-malarials.
    Skinner-Adams TS; Stack CM; Trenholme KR; Brown CL; Grembecka J; Lowther J; Mucha A; Drag M; Kafarski P; McGowan S; Whisstock JC; Gardiner DL; Dalton JP
    Trends Biochem Sci; 2010 Jan; 35(1):53-61. PubMed ID: 19796954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of piperazine-based hydroxamic acid inhibitors against falcilysin, an essential malarial protease.
    Chance JP; Fejzic H; Hernandez O; Istvan ES; Andaya A; Maslov N; Aispuro R; Crisanto T; Nguyen H; Vidal B; Serrano W; Kuwahara B; Pugne Andanado C; Goldberg DE; Mallari JP
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1846-1848. PubMed ID: 29691139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.